Women's health and digital radiography specialist Hologic achieved an 8% rise in revenues during the second quarter ended March 29, racking up $50.3 million compared with $46.4 million over the same period a year earlier. Net income was down markedly,
Women's health and digital radiography specialist Hologic achieved an 8% rise in revenues during the second quarter ended March 29, racking up $50.3 million compared with $46.4 million over the same period a year earlier. Net income was down markedly, however: $383,000 compared with $4.43 million in 2Q 2002. The earlier results reflected a $4.4 million tax refund from the Bush administration's Economic Stimulus Bill. Pretax income increased to $435,000 from $3000 in the second quarter FY 2002. The company achieved this improvement despite the increased investment in sales and service in connection with its transition to a direct sales and service organization for mammography products.
During the second quarter, Hologic shipped 14 Selenia full-field digital mammography systems. Eleven were recognized in revenue during the quarter. At the end of March 2003, the company had a backlog of 40 Selenia orders. On April 24, the firm announced the launch of Selenia sales in the U.K.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.